# This super composite rating is the result of a weighted average of the rankings based on the following ratings.

*biotech · news · 2026-05-30 · MarketScreener*

## Key points

- The Trader rating uses a weighted average emphasizing 4-month EPS Revisions and Valuation metrics.
- The Investor rating uniquely incorporates 1-year EPS Revisions into its composite calculation.
- Global composite ratings require company coverage by at least 4 of 5 specific sub-ratings.
- The Quality composite rating only calculates if at least 2 out of 3 quality sub-ratings are present.

Trader This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Investor This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Global This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions. Quality This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

[Read the full story on MarketScreener](https://www.marketscreener.com/news/immatics-presents-clinical-activity-of-ima203cd8-prame-cell-therapy-in-hard-to-treat-gynecologic-can-ce7f5dd8db89f523)

---

Canonical: https://newsio.io/n/b92f87cf-4bb2-46a5-9de5-ec90764116b7/this-super-composite-rating-is-the-result-of-a-weighted-average-of-the-rankings
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works